Management of candidal vulvovaginitis in pregnant women
Keywords:
candidiasis, embarazo, tratamiento, factores de riesgoAbstract
Candidal vulvovaginitis is a common infection in pregnant women, caused by Candida albicans. During pregnancy, hormonal and physiological changes promote the development of this fungus, with a prevalence of up to 30 %, particularly during the third trimester. Risk factors include increased estrogen production, increased vaginal glycogen generation, altered immunosuppression during pregnancy, and changes in vaginal pH. The objective of this research is to describe the current status of the diagnosis and treatment of vulvovaginal candidiasis in pregnant women. Research published in PubMed, Scopus, and Google Scholar over the last seven years on pathophysiology, prevalence, risk factors, and treatment was examined. The infection presents with pruritus, irregular vaginal discharge, and discomfort, and has maternal-fetal repercussions such as premature birth and transmission to the newborn. Diagnosis is based on clinical examination and microorganism cultures. The main therapy consists of topical antifungals such as clotrimazole and miconazole, which are considered safe during pregnancy. In addition, prevention through hygiene measures and the use of appropriate clothing is emphasized. Early identification and appropriate treatment are essential to avoid complications.
Keywords: candidiasis, pregnancy, treatment, risk factors
Downloads
References
1. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2020;33(2):e00130-19.
2. Bradshaw CS, Morton AN, Garland SM, Morris MB, Moss LM, Fairley CK. Evaluation of a point-of-care test, BVBlue, and clinical diagnosis for the detection of bacterial vaginosis. Clin Infect Dis. 2021;52(3):337-42.
3. Sobel JD, Nyirjesy P, Nagappan V. Laboratory diagnosis of vulvovaginal candidiasis: a new era. Clin Microbiol Rev. 2021;34(1):e00010-20.
4. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2019;114(2 Pt 2):281-4.
5. Cassone A, Sobel JD. Experimental models of vaginal candidiasis and their relevance to human candidiasis. Infect Immun. 2019;87(4):e00810-18.
6. Mendling W, Brasch J. Guideline vulvovaginal candidosis (AWMF 015/072), 2018. Mycoses. 2019;62(6):423-8.
7. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214(1):15-21.
8. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905-27.
9. Yano J, Sobel JD, Nyirjesy P, Sobel R, Williams VL, Yu Q, et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019;19(1):48.
10. Xiao S, Li Y, Zhao M, Wang Y, Shi L, Wang J. The detection of Candida albicans in vaginal secretions and the relationship to miscarriage. BMC Pregnancy Childbirth. 2020;20(1):532
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Heidi Nicole Salazar Zamora, Lisbeth Aracelly Yucailla Curay, Sylvia del Pilar Núñez Arroba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ACCESS AND DISTRIBUTION POLICY
All published articles are open access contributions, which are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is properly cited.
